Baxter International dividend yield – Baxter International Announces Quarterly Dividend

Trending News 🌥️

Baxter International ($NYSE:BAX) is a global medical products and services company. It operates in two segments: BioScience and Medical Products. The BioScience segment offers products and services for the treatment of hemophilia, immune disorders, inflammation, and other chronic and acute medical conditions. The Medical Products segment provides intravenous (IV) solutions and nutrition products, infusion systems and devices, parenteral nutrition therapies, respiratory therapies, and other therapies. The company announced a quarterly dividend of $0.29 per share, which is in line with previous quarters.

The dividend is payable on January 3 to shareholders of record as of December 2. The ex-dividend date is December 1. This dividend adds to the company’s strong track record of returning cash to shareholders. It is a reliable dividend paying stock for income investors.

Dividends – Baxter International dividend yield

This is an increase from the $1.08 and $0.96 dividends per share that were issued in the last two fiscal years. Baxter’s dividend yields from 2020 to 2022 are 1.1%, 1.34%, and 1.51%, respectively. The company’s three-year average dividend yield is 1.32%. Baxter International Inc. is a global medical products company that develops, manufactures, and markets products to treat hemophilia, kidney disease, immune disorders, and other chronic and acute medical conditions.

The company’s product portfolio includes biotherapeutics, recombinant proteins, and blood-based therapies. Baxter also provides a broad range of services to help hospitals, renal centers, and other healthcare providers improve patient care and reduce costs.

About the Company

Price History

This is the third consecutive quarter in which Baxter has increased its dividend. The company’s products are used in a variety of settings, including hospitals, clinics, home care, and dialysis centers. Live Quote…

VI Analysis

Investors who are interested in companies with strong dividend potential and high profitability would be interested in BAXTER INTERNATIONAL. This company is classified as a ‘cheetah’, meaning it has achieved high revenue or earnings growth but is considered less stable due to lower profitability. Despite this, the company has a high health score of 8/10, indicating that it is capable of safely riding out any crisis without the risk of bankruptcy. More…

VI Peers

Baxter International Inc is a large medical device company. Its main competitors are Utah Medical Products Inc, Clarity Medical Group Holding Ltd, and Merit Medical Systems Inc.

– Utah Medical Products Inc ($NASDAQ:UTMD)

The company’s market cap is $313.74 million and its ROE is 11.43%. Utah Medical Products, Inc. engages in the design, manufacture, and marketing of medical devices. It operates through the following segments: Pregnancy & Newborn, Patient Care, and Animal Health. The Pregnancy & Newborn segment offers a line of products used by obstetricians, gynecologists, and neonatal caregivers for the health and well-being of pregnant women and their babies. The Patient Care segment provides a line of products used by hospitals, clinics, and home healthcare providers for the treatment of respiratory and other conditions. The Animal Health segment offers a line of products used by veterinarians for the health and well-being of animals.

– Clarity Medical Group Holding Ltd ($SEHK:01406)

According to Clarity Medical Group Holding Ltd’s market cap as of 2022, the company is worth 599.47 million. Clarity Medical Group Holding Ltd is a Medical Group that provides healthcare services. The company was founded in 2014 and is headquartered in Hong Kong.

– Merit Medical Systems Inc ($NASDAQ:MMSI)

Medstronic is a medical device company that manufactures and sells a variety of medical devices and equipment. The company has a market cap of 3.29B as of 2022 and a ROE of 5.86%. Medtronic’s products are used in a variety of medical procedures, including cardiac surgery, vascular surgery, and neurology.

Summary

Investors looking for stability and income may find appeal in Baxter International (BAX), a large medical device company. Baxter has a strong financial position, with a credit rating of A from Standard & Poor’s. The company’s product portfolio is diversified, with offerings in renal care, medication delivery, nutrition, and biosurgery. Baxter’s products are used in hospitals, clinics, and home settings around the world.

The company has a growing presence in emerging markets, which should help drive future growth. Baxter has a strong track record of operational execution and delivering on its financial commitments. Baxter is a well-run company with a solid financial position, and looks like an attractive investment for those seeking stability and income.